
|Articles|November 2, 2012
Similar bleeding rates seen with two anticoagulants
Bleeding rates associated with new use of dabigatran (Pradaxa, Boehringer Ingelheim) do not appear to be higher than bleeding rates associated with new use of warfarin, according to an FDA safety review of post-market reports of serious bleeding events.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
Ixekizumab, Tirzepatide Maintains Efficacy in Psoriatic Disease
4
Measles Resurgence Exposes US Vaccine Policy Risks, Experts Warn
5






































